By Dr Adam Jacob Bryant

Book Chapters

Bryant A, 2021, 'Elotuzumab', in Resistance to Targeted Anti-Cancer Therapeutics, Springer International Publishing, pp. 73 - 82, http://dx.doi.org/10.1007/978-3-030-73440-4_6

Bryant A; Atkins H, 2017, 'Autoimmune disorders', in Clinical Manual of Blood and Bone Marrow Transplantation, pp. 221 - 228, http://dx.doi.org/10.1002/9781119095491.ch25

Journal articles

Kurniawan S; Hwang A; Doo NW; King T; Bryant C; Zhang J; Whelan K; Fani-Molky P; Kidson-Gerber G; Bosco A; Hamad N; Parmar G; Kwok F; Lai S; Ling S; Ho PJ; McCaughan G; Bryant A, 2026, 'Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter Study', Asia Pacific Journal of Clinical Oncology, http://dx.doi.org/10.1111/ajco.70101

Kwan G; Kwan T; Fernando S; Lee F; Lin M; Yun J; Bryant A; Ling S; Toong C, 2026, 'Comparative performance of Freelite and N-Latex serum free light chain assays across a multicentre New South Wales cohort', Pathology, 58, pp. S67 - S67, http://dx.doi.org/10.1016/j.pathol.2026.01.293

Zhong S; Ashraf MA; Dhir V; Matta L; Bryant A; McEwan A; Watson A-M; Hua M; Ng S; Hsu D; Dunlop L; Hsu H; Sungala N; Motum P; Beaton B, 2026, 'Duffy-null-associated absolute neutrophil count (DANC): an audit from south-western Sydney evaluating the neutrophil lower reference range for patients with DANC', Pathology, 58, pp. S64 - S64, http://dx.doi.org/10.1016/j.pathol.2026.01.282

Sim S; Bryant A; Forsyth C; Motorna O; Brotchie J; Hocking J; Yong A; Chien N; Kerridge I; Lai HC; Solterbeck A; Traficante R; Jocic M; Quach H, 2025, 'Interim analysis of efficacy and safety for ALLG MM25 (Viber-M): A phase I b/II study of venetoclax, iberdomide and dexamethasone for patients in first or second relapse of multiple myeloma with t(11;14)', Blood, 146, pp. 249 - 249, http://dx.doi.org/10.1182/blood-2025-249

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Hájek R; Kim K; Grosicki S; Sia H; Bryant A; Pitombeira de Lacerda M; Martinez GA; Sureda Balarí A; Sandhu I; Cerchione C; Ganly P; Dimopoulos MA; Fu C; Garg M; Abdallah AO; Gatt ME; Oriol Rocafiguera A; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Ficek J; Mantero A; Pirooz N; Varghese S; Lee J; McKeown A; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Mukhopadhyay P; Nielsen J; Opalinska J; Mateos MV, 2025, 'Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial', Lancet Oncology, 26, pp. 1067 - 1080, http://dx.doi.org/10.1016/S1470-2045(25)00330-4

Lim KJC; Wellard C; Moore E; Gration B; Augustson B; Mollee P; Zhang J; Doo NW; Ringkowski S; Bryant A; Ninkovic S; Hamad N; Mccaughan G; Kumar S; Spencer A; Quach H, 2024, 'Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry', BLOOD, 144, pp. 1951 - 1952, http://dx.doi.org/10.1182/blood-2024-207609

Bryant A; Quach H, 2024, 'Biomarker-directed therapy in multiple myeloma', Current Opinion in Oncology, 36, pp. 600 - 609, http://dx.doi.org/10.1097/CCO.0000000000001091

Li EW; Jones E; Bryant C; King T; Talaulikar D; Ng JY; Bryant A; Ridha Z; Doo NW; Menzies A; Ling S; Ho SJ; Abadir E; Vanguru V; Joshua D; Ho PJ, 2024, 'A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies', European Journal of Haematology, 113, pp. 521 - 529, http://dx.doi.org/10.1111/ejh.14266

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Ribas de Almeida AC; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Pitombeira de Lacerda M; Martinez GA; Balarí AMS; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah AO; Oriol A; Gatt ME; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; McKeown A; McNamara S; Zhou X; Nichols M; Lewis E; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Opalinska J; Mateos MV, 2024, 'Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma', New England Journal of Medicine, 391, pp. 393 - 407, http://dx.doi.org/10.1056/NEJMoa2405090

Tong MH; Kwok A; Walsh A; Heydon P; Koh ES; McNamara N; Bryant A, 2024, 'Isolated Ocular Relapse of Acute Myeloid Leukaemia Post Allogeneic Stem Cell Transplant', Case Reports in Ophthalmological Medicine, 2024, pp. 2235819, http://dx.doi.org/10.1155/2024/2235819

Al‐Ammari M; Hsu D; Bryant A, 2024, 'Myeloma‐associated hemophagocytic lymphohistiocytosis – A comprehensive case study and a novel chemotherapy‐free approach with anakinra', eJHaem, 5, pp. 1057 - 1062, http://dx.doi.org/10.1002/jha2.975

Ponraj R; Bryant A; Dunlop L; Range H; Cobrador C; Ling S; Hsu D, 2023, 'Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA', Blood Cancer Journal, 13, pp. 113, http://dx.doi.org/10.1038/s41408-023-00885-9

Plesner T; Harrison SJ; Quach H; Lee C; Bryant A; Vangsted A; Estell J; Delforge M; Offner F; Twomey P; Choeurng V; Li J; Hendricks R; Ruppert SM; Sumiyoshi T; Miller K; Cho E; Schjesvold F, 2023, 'Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma', Clinical Hematology International, 5, pp. 43 - 51, http://dx.doi.org/10.1007/s44228-022-00023-5

McCaughan GJ; Verma A; Ling S; Lavee O; Moore JJ; Bryant A, 2021, 'Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres', Bone Marrow Transplantation, 56, pp. 738 - 740, http://dx.doi.org/10.1038/s41409-020-01086-9

Othman J; Greenwood M; Moore J; Larsen S; Watson AM; Arthur C; Bhattacharyya A; Bilmon I; Blyth E; Bryant A; Bryant C; Dunlop L; Fay K; Gibson J; Hamad N; Kerridge I; Kwan J; Ma D; Micklethwaite K; Milliken S; Panicker S; Stevenson W; Withers B; Wilcox L; Tran S; Gottlieb DJ, 2020, 'Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG', Biology of Blood and Marrow Transplantation, 26, pp. 1868 - 1875, http://dx.doi.org/10.1016/j.bbmt.2020.06.030

Keane C; Fearnhead NS; Bordeianou LG; Christensen P; Espin Basany E; Laurberg S; Mellgren A; Messick C; Orangio GR; Verjee A; Wing K; Bissett IP; An V; Bryant A; Byrne C; Chen T; Croft S; Clark D; Gladman M; Heriot A; Kariappa S; Keck J; Lubowski D; Dinning P; Khera A; Kirkwood K; Petersen D; Sloots K; Totten B; Weston M; Andersen P; Bachmann C; Barht H; Emmertsen K; Faaborg P; Gögenur I; Ingerslev P; Isaksen D; Iversen H; Iversen L; Jacobsen K; Jansen T; Jocobsen I; Juul T; Kjær D; Krogh K; Majgaard M; Mynster A; Neuenschwander A; Nielsen C; Nielsen R; Nielsen M; Nielsen T; Olsen J; Poulsen B; Rahr H; Snedker B; Sørensen G; Stolzenburg T; Vaabengaard P; Acheson A; Andreyev J; Bach S; Battersby N; Bradbury J; Brown S; Cecil T; Chapman S; Chapman M; Chave H; Cook T; Cuffy L; Davies J; Dawson C; Dixon J; Duff S; Edwards C; Geh I; Hamilton C; Hancock L; Harji D; Hill J; Holtham S; Jenkins J; Johnston R; Kapur S; Maxwell-Armstrong C; McArthur D; Moran B; Norton C; Nugent K; Pateman L; Perston Y; Rockall T; Sagar P; Saunders M; Sebag-Montefiore D; Senapati A; Singh B; Skaife P, 2020, 'International consensus definition of low anterior resection syndrome', ANZ Journal of Surgery, 90, pp. 300 - 307, http://dx.doi.org/10.1111/ans.15421

Bryant A; Mallick R; Huebsch LB; Allan DS; Atkins H; Anstee G; Bence-Bruckler I; Hamelin L; Hodgins M; Sabloff M; Scrivens N; Maze D; Bredeson CN; Kekre N, 2017, 'Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant', Biology of Blood and Marrow Transplantation, 23, pp. S360 - S361, http://dx.doi.org/10.1016/j.bbmt.2016.12.307

Bryant A; Mallick R; Huebsch LB; Allan DS; Atkins H; Anstee G; Bence-Bruckler I; Hamelin L; Hodgins M; Sabloff M; Scrivens N; Maze DC; Bredeson CN; Kekre N, 2016, 'Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant', Blood, 128, pp. 5782 - 5782, http://dx.doi.org/10.1182/blood.v128.22.5782.5782

Palma CA; Al Sheikha D; Lim TK; Bryant A; Vu TT; Jayaswal V; Ma DDF, 2014, 'MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia', Molecular Cancer, 13, http://dx.doi.org/10.1186/1476-4598-13-79

Dalal BI; Al Mugairi A; Pi S; Lee SY; Khare NS; Pal J; Bryant A; Vakil AP; Lau S; Abou Mourad YR, 2014, 'Aberrant Expression of CD13 Identifies a Subgroup of Standard-Risk Adult Acute Lymphoblastic Leukemia With Inferior Survival', CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 14, pp. 239 - 244, http://dx.doi.org/10.1016/j.clml.2013.10.003

Bryant A; Nivison-Smith I; Pillai ES; Kennedy G; Kalff A; Ritchie D; George B; Hertzberg M; Patil S; Spencer A; Fay K; Cannell P; Berkahn L; Doocey R; Spearing R; Moore J, 2014, 'Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients', Bone Marrow Transplantation, 49, pp. 17 - 23, http://dx.doi.org/10.1038/bmt.2013.142

Bilmon I; Nivison-Smith I; Hertzberg M; Ritchie D; Greenwood M; Spencer A; Kennedy G; Bryant A; Moore J, 2014, 'Outcomes following second allogeneic haematopoietic transplants using fludarabine–melphalan conditioning', Bone Marrow Transplantation, 49, pp. 852 - 853, http://dx.doi.org/10.1038/bmt.2014.23

Bryant A; Palma CA; Jayaswal V; Yang YH; Lutherborrow MA; Ma DD, 2012, 'miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death', Molecular Cancer, 11, pp. 8, http://dx.doi.org/10.1186/1476-4598-11-8

Loi TH; Campain A; Bryant AJ; Molloy T; Lutherborrow MA; Turner J; Yang YH; Ma DD, 2011, 'Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profiling', BMC Medical Genomics, 4, pp. 1 - 10, http://www.biomedcentral.com/1755-8794/4/27

Lutherborrow MA; Bryant AJ; Jayaswal V; Agapiou DJ; Palma CA; Yang YH; Ma DD, 2011, 'Expression profiling of cytogenetically normal acute myeloid leukemia identifies MicroRNAs that target genes involved in monocytic differentiation', American Journal of Hematology, 86, pp. 2 - 11, http://dx.doi.org/10.1002/ajh.21864

Sasson SC; Smith S; Seddiki N; Zaunders J; Bryant AJ; Koelsch KK; Weatherall CJ; Munier CM; McGinley C; Yeung J; Mulligan S; Moore JJ; Cooper DA; Milliken ST; Kelleher AD, 2010, 'IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers', Cytokine, 50, pp. 58 - 68

Bryant A; Lutherborrow MA; Ma DD, 2009, 'The clinicopathological relevance of microRNA in normal and malignant haematopoiesis', Pathology, 41, pp. 204 - 213

Bryant A; Milliken ST, 2008, 'Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma', Biology of Blood and Marrow Transplantation, 14, pp. 601 - 602, http://dx.doi.org/10.1016/j.bbmt.2008.01.010

Bryant A; Low J; Austin SA; Joseph JE, 2008, 'Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T`s score and particle gel immunoassay', British Journal of Haematology, 143, pp. 721 - 726

Bryant A; Moore J, 2006, 'Rituximab and its potential for the treatment of rheumatoid arthritis', Therapeutics and Clinical Risk Management, 2, pp. 207 - 212, http://dx.doi.org/10.2147/tcrm.2006.2.2.207

Bryant A; Moore J, 2006, 'Rituximab and its potential for the treatment of rheumatoid arthritis', Therapeutics and Clinical Risk Management, 2, pp. 207 - 212, http://dx.doi.org/10.2147/tcrm.s22207

Conference Papers

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Lacerda MPD; Martinez GA; Balari AMS; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah A-O; Gatt ME; Oriol A; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; Lee J; Mckeown A; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Mateos MV, 2025, 'Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial', in BLOOD, ELSEVIER, FL, Orlando, pp. 772 - 774, presented at 66th Annual Meeting of the American-Society-of-Hematology (ASH), FL, Orlando, 06 December 2025 - 09 December 2025, http://dx.doi.org/10.1182/blood-2024-200336

Bryant C; Abadir E; Doo NW; Bryant A; McCaughan G; Yang S; Vanguru V; King T; Joshua D; Ho PJ, 2023, 'Failure to clear circulating tumor cells after one week of daratumumab, bortezomib and dexamethasone is associated with a reduced progression-free survival for myeloma patients', in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, CIG MEDIA GROUP, LP, pp. S73 - S73

Li E; Bryant C; Jones E; King T; Talaulikar D; Ng J; Bryant A; Ridha Z; Doo NW; Ling S; Ho PJ; Joshua D, 2023, 'The efficacy and safety of prednisone, cyclophosphamide, doxorubicin and carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy', in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, CIG MEDIA GROUP, LP, pp. S196 - S196

Bryant AJ; Pillai E; Kennedy G; Kalff A; Ritchie D; George B; Hertzberg M; Patil SS; Spencer A; Fay K; Cannell P; Berkahn L; Doocey R; Spearling R; Nivison-Smith I; Moore J, 2011, 'A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998-2008', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, pp. 1772 - 1772, presented at 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, CA, San Diego, 10 December 2011 - 13 December 2011

Conference Abstracts

Khalaf Z; Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho P; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda M; Martinez G; Balari A; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah A-O; Gatt M; Oriol A; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; Lee J; McKeown A; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Opalinska J; Mateos M, 2025, 'Belantamab Mafodotin plus Bortezomib plus Dexamethasone vs Daratumumab plus Vd in RRMM: Updates on Overall Survival and Efficacy in DREAMM-7', in BRITISH JOURNAL OF HAEMATOLOGY, WILEY, SCOTLAND, Glasgow, Vol. 206, presented at 65th Annual Scientific Meeting of the British-Society-for-Haematology, SCOTLAND, Glasgow, 27 April 2025 - 29 April 2025

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; Almeida ACD; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Lacerda MPD; Garcia EG; Balari AS; Kazeem B; Pirooz N; Lee J; Baig H; Eccersley L; Robak P; Mateos M-V; Varghese S, 2025, 'DREAMM-7 Study of Belantamab Mafodotin plus Bortezomib (V) plus Dexamethasone (d) vs Daratumumab plus Vd in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy', in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, CIG MEDIA GROUP, LP, Vol. 25

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; Almeida ACD; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Garcia EG; Balari AS; Kazeem B; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Robak P; Mateos V, 2025, 'DREAMM-7 Study of Belantamab Mafodotin plus Bortezomib plus Dexamethasone vs Daratumumab plus Bortezomib plus Dexamethasone in Relapsed/ Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy', in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, CIG MEDIA GROUP, LP, Vol. 25

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; de Almeida AC; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Aparecida-Martinez G; Balari AS; Kazeem B; Lin CP; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Khalaf Z; Mateos M-V, 2025, 'Outcomes in Second-Line Lenalidomide-Refractory Patients in the Phase 3 DREAMM-7 Study of Belantamab Mafodotin, Bortezomib (V) and Dexamethasone (d) vs Daratumumab-Vd in RRMM', in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, CIG MEDIA GROUP, LP, Vol. 25

Marivel A-MJ; Roberts TL; Descallar J; Aung WPP; Cheng J; Becker TM; James A; Ma Y; Bryant A; Ling S, 2023, 'Multiple Myeloma in the Culturally and Linguistically Diverse Southwestern Sydney, Australia', in BLOOD, ELSEVIER, CA, San Diego, Vol. 142, presented at 65th Annual Meeting of the American-Society-of-Hematology (ASH), CA, San Diego, 09 December 2023 - 12 December 2023, http://dx.doi.org/10.1182/blood-2023-185193

Bryant C; Abadir E; Doo NW; Bryant A; McCaughan G; Yang S; Vanguru V; King T; Joshua D; Ho PJ, 2023, 'P-070 Failure to clear circulating tumor cells after one week of daratumumab, bortezomib and dexamethasone is associated with a reduced progression-free survival for myeloma patients', in Clinical Lymphoma Myeloma and Leukemia, Elsevier BV, Vol. 23, pp. S73 - S73, http://dx.doi.org/10.1016/s2152-2650(23)01688-9

Li E; Bryant C; Jones E; King T; Talaulikar D; Ng J; Bryant A; Ridha Z; Doo NW; Ling S; Ho PJ; Joshua D, 2023, 'P-289 The efficacy and safety of prednisone, cyclophosphamide, doxorubicin and carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy', in Clinical Lymphoma Myeloma and Leukemia, Elsevier BV, Vol. 23, pp. S196 - S196, http://dx.doi.org/10.1016/s2152-2650(23)01907-9

Plesner T; Harrison SJ; Quach H; Lee CH; Bryant A; Vangsted AJ; Estell J; Delforge M; Offner F; Twomey P; Choeurng V; Li J; Hendricks R; Sumiyoshi T; Miller K; Choi E; Schjesvold FH, 2021, 'A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)', in BLOOD, ELSEVIER, GA, Atlanta, Vol. 138, presented at 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), GA, Atlanta, 11 December 2021 - 14 December 2021, http://dx.doi.org/10.1182/blood-2021-147418

McCaughan GJ; Verma A; Ling S; Lavee O; Moore J; Bryant A, 2020, 'Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethathasone (CyBorD) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres', in BLOOD, ELSEVIER, ELECTR NETWORK, Vol. 136, presented at 62nd Annual Meeting of the American-Society-of-Hematology (ASH), ELECTR NETWORK, 05 December 2020 - 08 December 2020, http://dx.doi.org/10.1182/blood-2020-139269

McCaughan GJ; Tran S; Durrant S; Harrison SJ; Morton J; Horvath N; Spencer A; Kerridge IH; Er JAK; Barge L; Bryant A; Filshie RJ; Choong E; Lai HC; Tiley C; Mills AK; Butler A; Moore J; Hertzberg M; Kennedy GA; Ho PJ; Sidiqi MH; Bashford J; Routledge D; Taylor K; Lee CH; Kalff A; Xia W; Hamad N, 2020, 'Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study', in BLOOD, AMER SOC HEMATOLOGY, Vol. 136, http://dx.doi.org/10.1182/blood-2020-138991

Haack R; Mallik S; Sungala N; Bryant A; Ho LL; Motum P, 2019, 'COPPER DEFICIENCY: DON'T YOU FORGET ABOUT ME.', in INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, WILEY, Vol. 41, pp. 68 - 68, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000487566000106&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Watson A-M; Bryant A; Davison S; Ling S; Levy M, 2016, 'Treatment of Otherwise Ineligible Donors for Hepatitis B Prior to Matched Sibling Allogeneic Stem Cell Transplant', in BONE MARROW TRANSPLANTATION, SPRINGERNATURE, SPAIN, Valencia, Vol. 51, pp. S140 - S140, presented at 42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, SPAIN, Valencia, 03 April 2016 - 06 April 2016

Bryant A; Kershaw G; Zebeljan D; Motum P; Das R, 2013, 'Factor VIII inhibitor and pulmonary embolism developing in a patient after meningioma resection: clinical and laboratory aspects', in JOURNAL OF THROMBOSIS AND HAEMOSTASIS, WILEY-BLACKWELL, Vol. 11, pp. 1021 - 1021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000331833604400&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page